ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: BCR-ABL inhibition prevents activation of ISR in K562 cell line derived from a chronic myeloid leukemia (CML) patient and makes the tumor cells more vulnerable to metabolic stress (Kato et al., 2018).